Last reviewed · How we verify

NCT04116892: CAOLMHS

Comparative Analysis of Large Macular Hole Surgeries

Status unknown NA Last updated 27 October 2020
What this trial tests

NA trial testing the Cover group in Macular Holes in 100 participants. Status unknown.

Timeline
1 May 2019
Primary endpoint
30 June 2021
30 September 2021

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment100
Start date1 May 2019
Primary completion30 June 2021
Estimated completion30 September 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 75, any sex, with Macular Holes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the anatomical and visual outcomes in a large series of patients affected by idiopathic macular holes larger than 400 µm treated using pars plana vitrectomy and gas tamponade combined with internal limiting membrane (ILM) peeling or the inverted internal limiting membrane flap technique. A part of the participants will receive internal limiting membrane peeling,whil the other will receive the inverted internal limiting membrane flap technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Macular Holes

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04116892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing